Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 4/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | GRM8 | O00222 | 1/20 | 0.44 |
| ▸ | GRM6 | O15303 | 1/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.44 |
| ▸ | GSR | P00390 | 1/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.44 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.44 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.44 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.44 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.44 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aspartic Acid SCHEMBL165913 | 0.88 | SLC1A3 (0.48) | MCHR1SLC1A3SLC1A2SLC1A1CYP1A2 | |
| SCHEMBL160943 | 0.75 | HTR2A (0.55) | CYP1A2HTR2BHTR2AHTR2CDRD2 | |
| Glutamic Acid SCHEMBL158773 | 0.74 | GRM8 (0.49) | SLC1A3SLC1A2SLC1A1CYP1A2GRM8 | |
| Lorcaserin SCHEMBL15389716 | 0.73 | HTR2A (0.62) | HTR2BHTR2AHTR2CHTR1AHRH1 | |
| Lorcaserin SCHEMBL174027 | 0.73 | HTR2A (0.62) | HTR2BHTR2AHTR2CHTR1AHRH1 | |
| Glutamic Acid SCHEMBL10475707 | 0.71 | GRIK1 (0.60) | SLC1A3SLC1A2SLC1A1CYP1A2GRM8 | |
| SCHEMBL6883015 | 0.70 | MAOA (0.59) | CYP1A2HTR2BHTR2AHTR2CDRD2 | |
| Nitric Acid SCHEMBL165780 | 0.70 | HTR2A (0.50) | MCHR1CYP1A2HTR2BHTR2AHTR2C | |
| Glutamic Acid SCHEMBL26698409 | 0.70 | CYP1A2 (0.58) | SLC1A3SLC1A2SLC1A1CYP1A2GRM8 | |
| Serine SCHEMBL3614528 | 0.69 | SLC1A3 (0.55) | SLC1A3SLC1A2SLC1A1CYP1A2GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611449-A1 | ADMINISTRATION OF LORCASERIN TO INDIVIDUALS WITH RENAL IMPAIRMENT | Arena Pharmaceuticals, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| EP-2611427-A2 | MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT& xA; | Arena Pharmaceuticals, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012030953-A1 | 5-HT2C RECEPTOR AGONISTS IN THE TREATMENT OF DISORDERS AMELIORATED BY REDUCTION OF NOREPINEPHRINE LEVEL | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012030927-A2 | MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012030939-A1 | ADMINISTRATION OF LORCASERIN TO INDIVIDUALS WITH RENAL IMPAIRMENT | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |